- Home
- HXHX vs INTS Comparison
HXHX vs INTS Comparison
Compare HXHX & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXHX
- INTS
- Stock Information
- Founded
- HXHX 2003
- INTS 2012
- Country
- HXHX China
- INTS United States
- Employees
- HXHX N/A
- INTS N/A
- Industry
- HXHX Trucking Freight/Courier Services
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- HXHX Industrials
- INTS Health Care
- Exchange
- HXHX Nasdaq
- INTS Nasdaq
- Market Cap
- HXHX 36.9M
- INTS 30.8M
- IPO Year
- HXHX 2025
- INTS 2023
- Fundamental
- Price
- HXHX $1.71
- INTS $1.04
- Analyst Decision
- HXHX
- INTS Strong Buy
- Analyst Count
- HXHX 0
- INTS 3
- Target Price
- HXHX N/A
- INTS $8.50
- AVG Volume (30 Days)
- HXHX 2.3M
- INTS 37.8K
- Earning Date
- HXHX 01-01-0001
- INTS 05-08-2025
- Dividend Yield
- HXHX N/A
- INTS N/A
- EPS Growth
- HXHX N/A
- INTS N/A
- EPS
- HXHX 0.30
- INTS N/A
- Revenue
- HXHX $25,712,499.00
- INTS N/A
- Revenue This Year
- HXHX N/A
- INTS N/A
- Revenue Next Year
- HXHX N/A
- INTS N/A
- P/E Ratio
- HXHX $5.91
- INTS N/A
- Revenue Growth
- HXHX N/A
- INTS N/A
- 52 Week Low
- HXHX $1.58
- INTS $1.27
- 52 Week High
- HXHX $6.29
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- HXHX N/A
- INTS 21.48
- Support Level
- HXHX N/A
- INTS $1.78
- Resistance Level
- HXHX N/A
- INTS $1.94
- Average True Range (ATR)
- HXHX 0.00
- INTS 0.17
- MACD
- HXHX 0.00
- INTS -0.06
- Stochastic Oscillator
- HXHX 0.00
- INTS 3.75
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.